ApconiX is a team of world-renowned nonclinical safety experts with over 300 years of drug discovery and development expertise. We will work with you to provide the advice you need, at the right time to make better decisions on drug safety, from project initiation through to worldwide marketing approval. ApconiX has a team of experienced scientists covering all major safety disciplines, our own ion channel laboratory and a commitment to advancing the science of drug safety.
Whether you want to explore an ion channel as a new potential target or understand cardiovascular liability, ApconiX can help you with our electrophysiology expertise, customer-focused flexibility and high data quality. Importantly, ApconiX is uniquely positioned to help place these data in the right context for your programme and explain how they inform decision making.
You will benefit from:
Over 50% of drug safety failures are known to be related to the target itself. Understanding the role of your drug target in normal physiology, and any potential adverse consequences of its modulation, is the foundation on which to build the safety profile of your asset.
Our experienced toxicologists will conduct a thorough review of the literature and will identify and prioritise any issues that are relevant for further consideration. In collaboration with your team, we will provide a bespoke, succinct, risk-focused report that is directly aligned to your needs.
Target Safety Assessments can include:
Promising compounds are bought, sold and partnered at all stages of the drug development process. Our experts have conducted many Due Diligence reviews and can give you the assurance you need to make a commercially sound decision.
The Right Partner
Prior to any licencing deal, it is essential you have confidence that an asset is what it appears to be. Then to assign the right value, you need to know that the data and interpretations are robust, and that forward plans are realistic.
Having been involved in Due Diligence evaluations over many years, across multiple therapy areas and asset classes, ApconiX scientists have the experience you need to help you make the right commercial decision.
ApconiX will work seamlessly with your team to provide expert technical appraisal of the nonclinical safety and DMPK data.
Our aim is for you to complete the due diligence process fully aware of all potential technical and regulatory risks in order the shape the right financial deal, or walk away.
Working as part of your Due Diligence team, we will:
Safety risks are the leading cause of attrition in drug discovery and development. A well designed and delivered toxicology package can make the difference between success and failure. With our collective experience of more than 300 years in drug discovery and development, we have the unique capability to deliver a high quality, cost-effective preclinical safety package that perfectly aligns with your project.
Toxicology is a complex, multidisciplinary science that requires integration of diverse skill sets and creative thinking. Whatever your project issues, wherever you are on the drug discovery and development journey, our team approach gives you access to all the expertise you need to achieve your next milestone. Our world-leading expertise will guide you towards scientific and regulatory success.
Whatever the challenge you face, ApconiX has world renowned scientists in several key technical disciplines able to work with you on a flexible or on-going basis. We also have an extensive global network of experts that allows us to find the most effective solution to any problem. We will provide you with the best advice at the right time to make the best decisions for your project.
Our specialist areas include:
"The work was completed quickly and was good quality."
ApconiX Ltd has not received any endorsements.